Tasigna Carries The Unacceptable Risk of Developing Atherosclerosis and Amputation

There is growing evidence that Tasigna patients may be simply trading one deadly disease for another

Wednesday, September 19, 2018 - Amputation is one of the more unsettling elements of risk facing chemotherapy patients that are given Tasigna. Tasigna has been shown to cause rapid onset peripheral artery disease (PAD). PAD causes the arteries that lead to the extremities to become clogged with a fatty substance called plaque, narrowing the blood vessels and limiting the amount of oxygen and nutrient-rich blood that reaches the smallest capillaries in the feet and toes. When the blockage becomes extreme, the toes can blacken with irreversible and rapidly progressive tissue death where the only treatment is amputation. The official Tasigna website now lists amputation as a possible side effect of Tasigna. Incredibly, over the years that Novartis, maker of Tasigna was aware of the risks, cancer patients in the United States were kept in the dark.

Amputation is not the only devastating side effect that was kept from Tasigna patients. Sudden death from heart attack and permanent paralysis from strokes are also life-threatening side effects of Tasigna. More and more, Tasigna patients are holding Novartis accountable by speaking with a Tasigna lawyer and filing a claim against Novartis for negligence in rushing a deadly drug to market. Fighting cancer is difficult enough without having to battle Tasigna's deadly side effects. Cancer patients must decide which type of chemotherapy treatment they will receive so that they can make an informed decision. They are entitled to all of the facts about an anti-cancer chemotherapy drug's side effects.

Novartis hid Tasigna's side effects from their marketing staff and illegally set out to conspire with specialty pharmacists to sell drugs including Tasigna to an unsuspecting cancer public. Proper warning labels were placed on the drug in Canada when Novartis warned Canada's health department, Health Canada, that atherosclerosis and amputations were side effects of the drug. Novartis was fined by the US Department of Justice and paid $390 million for their deceptive marketing of Tasigna in the United States. The company was forced to update their US website to include the risks of atherosclerosis. "Decreased blood flow to the legs, heart, or brain. People who have recently been diagnosed with Ph+ CML and take TASIGNA may develop decreased blood flow to the legs, the heart, or brain. Get medical help right away if you suddenly develop any of the following symptoms, chest pain or discomfort, numbness or weakness, problems walking or speaking, leg pain, your leg feels cold, or change in the skin color of your leg."

Atherosclerosis is a permanent irreversible condition, unlike other chemotherapy side-effects such as nausea and tiredness that are temporary. Tasigna may be effective in helping cancer go into, and stay in remission, but an unacceptably high number of patients are left with a blood disease that is just as lethal as cancer they were originally saddled with. Tasigna patients may be merely trading one deadly disease for another.

More Recent Tasigna Atherosclerosis Lawsuit News:

Lawyers for Tasigna Atherosclerosis Lawsuits

Attorneys handling Tasigna lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Tasigna lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Tasigna lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.